Showing results (421-430 of 592) with videos related to
Sort By:
Pageof 60
Genes|June 26, 2026
LANTERN 2: Association Between Gene Molecular Profile and STAS in Lung Adenocarcinoma: A Comparative Analysis in a Prospective Real-World PopulationCarolina Sassorossi, Davide Dalfovo, Elisa De Paolis, et al.Clinical Lung Cancer|October 12, 2019
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid BiopsyAlessandro Dal Maso, Martina Lorenzi, Elisa Roca, et al.JAMA Oncology|September 30, 2019
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical TrialGeorge W Sledge, Masakazu Toi, Patrick Neven, et al.Cancer Research|April 15, 2010
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapyGiulia Grisendi, Rita Bussolari, Luigi Cafarelli, et al.Future Oncology (London, England)|May 14, 2021
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further linesAlessandro Dal Maso, Martina Lorenzi, Alessandra Ferro, et al.International Journal of Molecular Sciences|April 14, 2026
LANTERN-XGB: An Interpretable Multi-Modal Machine Learning for Improving Clinical Decision-Making in Lung CancerDavide Dalfovo, Carolina Sassorossi, Elisa De Paolis, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapyMichele Milella, Carmen Nuzzo, Emilio Bria, et al.European Journal of Cancer (Oxford, England : 1990)|December 23, 2025
PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: A multicentric real-world studyMaria Vittoria Dieci, Grazia Vernaci, Chiara Colangelo, et al.Clinical Lung Cancer|February 9, 2021
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase InhibitorsMiriam Grazia Ferrara, Maurizio Martini, Ettore D'Argento, et al.Anticancer Research|September 12, 2013
HER2/neu gene determination in women screened for breast carcinoma: how screening programs reduce the skyrocketing cost of targeted therapyMatteo Brunelli, Erminia Manfrin, Emilio Bria, et al.Pageof 60